HC Wainwright Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price objective decreased by equities researchers at HC Wainwright from $185.00 to $140.00 in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 32.34% from the company’s current price.

Several other equities research analysts have also recently weighed in on the stock. Royal Bank Of Canada upped their price target on shares of Mirum Pharmaceuticals from $142.00 to $148.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Morgan Stanley lifted their price objective on shares of Mirum Pharmaceuticals from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Thursday, June 11th. CLSA set a $146.00 target price on Mirum Pharmaceuticals in a report on Monday, June 15th. Robert W. Baird increased their target price on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Finally, Wolfe Research began coverage on Mirum Pharmaceuticals in a report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $140.40.

Mirum Pharmaceuticals Stock Performance

MIRM stock opened at $105.79 on Thursday. Mirum Pharmaceuticals has a 1-year low of $50.25 and a 1-year high of $130.00. The business has a 50-day moving average price of $110.46 and a 200 day moving average price of $101.77. The company has a market capitalization of $6.45 billion, a P/E ratio of -7.77 and a beta of 0.52. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The business had revenue of $176.24 million for the quarter, compared to the consensus estimate of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The firm’s revenue was up 37.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.12) earnings per share. As a group, equities research analysts forecast that Mirum Pharmaceuticals will post -2.01 EPS for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $122.25, for a total value of $611,250.00. Following the completion of the sale, the chief financial officer directly owned 42,181 shares in the company, valued at $5,156,627.25. This trade represents a 10.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 2,721 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total value of $326,520.00. Following the transaction, the senior vice president directly owned 3,114 shares in the company, valued at approximately $373,680. The trade was a 46.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 67,155 shares of company stock valued at $7,185,662 in the last 90 days. Insiders own 8.32% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cullen Frost Bankers Inc. purchased a new stake in Mirum Pharmaceuticals in the fourth quarter valued at about $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in Mirum Pharmaceuticals in the fourth quarter worth about $32,000. CIBC Private Wealth Group LLC purchased a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth about $32,000. Quantbot Technologies LP purchased a new stake in shares of Mirum Pharmaceuticals during the third quarter worth about $33,000. Finally, Comerica Bank increased its holdings in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares in the last quarter.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum reported second-quarter revenue of $176.24 million, up 37.9% year over year and above the $166.33 million consensus estimate. The company also raised or reaffirmed full-year 2026 revenue guidance at $680 million-$700 million, ahead of Wall Street’s $675.1 million estimate. Mirum Pharmaceuticals Q2 earnings report
• Positive Sentiment: Analyst sentiment remains broadly favorable, with a consensus “Moderate Buy” rating and an average price target of $143.40, well above the recent trading level. Morgan Stanley previously raised its target to $150 and maintained an overweight rating. Mirum Pharmaceuticals analyst ratings
• Neutral Sentiment: The Q2 earnings call transcript provides additional management commentary for investors, but the supplied reports do not identify a specific new catalyst or change in the company’s development and commercialization outlook. Mirum Pharmaceuticals Q2 2026 earnings call transcript
• Negative Sentiment: Mirum posted a quarterly loss of approximately $0.80 per share on an adjusted basis, narrowly missing the $0.77 consensus estimate; the reported $1.06 per-share loss under another earnings measure was also below expectations. The loss widened from $0.12 per share a year earlier, highlighting continued profitability pressure. Mirum Pharmaceuticals Q2 loss report
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth $193,733.60, reducing her direct holdings by 59.09%. Because the transaction was made under a pre-arranged Rule 10b5-1 plan, it may be less concerning than discretionary selling, but it nevertheless adds modest selling pressure. Mirum Pharmaceuticals insider sale

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.